VLS Valneva SE

[Valneva SE] Declaration of shares and voting rights - May 2025

[Valneva SE] Declaration of shares and voting rights - May 2025

VALNEVA

Declaration of shares and voting rights

May 31, 2025

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: June 5, 2025

Number of shares

composing the share capital of Valneva 		Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total number of voting rights excluding suspended voting rights**
 



170,188,190



ordinary shares with a par value of €0.15 each





 		186,313,236 Double voting rights granted on 236,308 ordinary shares



 



Capital increase without preferential subscription rights (2,916,666 new ordinary shares issued) 		Between May 10 & May 26, 2025



 



 



On May 27, 2025 		186,188,914

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
05/06/2025

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Reports Positive Six-Month Antibody Persistence and Safety Pha...

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ® IXCHIQ® was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV)Antibody levels remained high after six months in both dose groups, although more robust with the full doseSix-month data confirm full dose selection for pivotal Phase 3 trial Saint-Herblain (France), June 5, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibod...

June 5, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva annonce des résultats positifs de Phase 2 à six mois sur la pe...

Valneva annonce des résultats positifs de Phase 2 à six mois sur la persistance des anticorps et l’innocuité de son vaccin à dose unique contre le chikungunya IXCHIQ® chez les enfants IXCHIQ® a été bien toléré par les enfants âgés d’un à onze ans indépendamment de la dose de vaccin reçue (dose complète ou demi-dose) ou d’une précédente infection au virus du chikungunyaLes niveaux d’anticorps demeurent élevés après six mois dans les deux groupes vaccinés et sont plus robustes dans le groupe ayant reçu une dose complète du vaccin Les données à six mois confirment la sélection d’une dose compl...

June 5, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

[Valneva SE] Declaration of shares and voting rights - May 2025

[Valneva SE] Declaration of shares and voting rights - May 2025 VALNEVA Declaration of shares and voting rights May 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: June 5, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized...

June 5, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025

[Valneva SE] Déclaration d’actions et de droits de vote - mai 2025 VALNEVA Déclaration d’actions et de droits de vote 31 mai 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 5 juin 2025 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droits de vote suspendus* Origine de la variation Date à laquelle cette variation a...

June 5, 2025 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Announces Availability of Documentation for its Combined Share...

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update Saint-Herblain (France), June 4, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined General Meeting (“the Meeting”) to be held on June 25, 2025 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France). The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the Board of Directors, and inst...

June 4, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch